Results 161 to 170 of about 27,293 (207)

The Dopamine D1 Receptors

1992
Many psychomotor signs and symptoms are influenced by the activity of dopaminergic neurons and by drugs that selectively interact with neuronal dopamine receptors. These include rigidity in Parkinson’s disease, hallucinations in schizophrenia and Alzheimer’s disease, dyskinesia in Huntington’s chorea, and spontaneous oral dyskinesia in the elderly ...
Hyman B. Niznik, Roger K. Sunahara, Hubert H. M. Van Tol, Philip Seeman, David M. Weiner, Tom M. Stormann, Mark R. Brann, Brian F. O’Dowd   +7 more
openaire   +1 more source

Brain D1 Dopamine Receptor in Alloxan-Induced Diabetes

Diabetes, 1992
Specific binding of [3H]SCH 23390 to dopamine D1 receptors in the striatum and olfactory tubercle in 14-day alloxan-induced diabetic rats was investigated. The Scatchard analysis revealed decreased D1 receptor density in the striatum (Bmax values were 548 ± 23 fmol/mg protein for the control and 466 ± 33 fmol/mg for the diabetic rats).
M, Salković, Z, Lacković
openaire   +2 more sources

Localization of dopamined D1-receptors in vertebrate retinae

Neurochemistry International, 1995
We used the fluorescent labelled dopamine D1-receptor antagonist Bodipy-SCH 23390 for the cellular localization of D1-ligand binding sites in the retinae of different vertebrates (teleosts, Xenopus, turtle, rat and rabbit). Competition experiments with unfixed cryosections of fish retina were performed to characterize the binding conditions of Bodipy ...
U D, Behrens, H J, Wagner
openaire   +2 more sources

Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines

European Journal of Pharmacology, 2003
We prepared a series of 18 novel substituted phenylbenzazepine congeners of the dopamine D1/D5 receptor partial-agonist SKF-83959 (R,S-3-methyl-6-chloro-7,8-dihydroxy-1-[3'-methylphenyl]-2,3,4,5-tetrahydro-1H-benzazepine) and characterized their potency and selectivity in assays of dopamine, 5-HT and adrenoceptors in rat brain tissue or membranes of ...
John L, Neumeyer, Nora S, Kula, Jack, Bergman, Ross J, Baldessarini   +3 more
openaire   +2 more sources

Selective Dopamine D1 and D2 Receptor Antagonists

1989
The concept of selective dopamine D1 and D2 receptor antagonists is rather new. Previously, dopamine receptor antagonism was evaluated simply as the ability to inhibit dopamine- or dopamine agonist-mediated behaviour or biochemical responses. In 1979 Kebabian and Calne introduced the dopamine D1 and D2 receptor concept based on differential linkage to ...
J, Hyttel, J, Arnt, M, van den Berghe
openaire   +2 more sources

The Multiplicity of the D1 Dopamine Receptor

1986
Dopaminergic neurotransmission is known to modulate a variety of behaviors, including ambulation (Ungerstedt and Arbuthnott, 1970; Pijnenburg et al., 1976), stereotyped behaviors (Creese and Iversen, 1973), self-stimulation (Phillips and Fibiger, 1973), conditioned avoidance responding (Seiden and Carlsson, 1963), stimulus control (Ho and Huang, 1975),
R B, Mailman, D W, Schulz, C D, Kilts, M H, Lewis, H, Rollema, S, Wyrick   +5 more
openaire   +2 more sources

The D1 dopamine receptor: new perspectives

Trends in Pharmacological Sciences, 1986
Abstract Several years ago, the D 1 receptor was dismissed as a ‘receptor in search of a function' and most CNS effects of dopaminergic drugs were attributed to interactions with the D 2 receptor. More recently, however, the development of selective antagonists has meant that the role of the D 1 receptor has begun to be reconsidered. John Kebabian
J.W. Kebabian, T. Agui, J.C. Van Oene, K. Shigematsu, J.M. Saavedra   +4 more
openaire   +1 more source

Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia

Molecular Neurobiology, 2014
Radioligand binding assays to rat striatal dopamine D1 receptors showed that brain lateralization of the dopaminergic system were not due to changes in expression but in agonist affinity. D1 receptor-mediated striatal imbalance resulted from a significantly higher agonist affinity in the left striatum.
Daniel, Farré, Ana, Muñoz, Estefanía, Moreno, Irene, Reyes-Resina, Júlia, Canet-Pons, Iria G, Dopeso-Reyes, Alberto J, Rico, Carme, Lluís, Josefa, Mallol, Gemma, Navarro, Enric I, Canela, Antonio, Cortés, José L, Labandeira-García, Vicent, Casadó, José L, Lanciego, Rafael, Franco   +15 more
openaire   +2 more sources

Repeated stimulation of dopamine D1 receptors enhances the effects of dopamine receptor agonists

European Journal of Pharmacology, 1990
Male Sprague-Dawley rats (200-250 g) received either twice daily injections of the selective D 1 agonist SKF 38393 (8.0 mg/kg s.c.) or saline for 21 days. For the last injection, both groups received SKF 38393 and were observed (30 min) for D 1 receptor-mediated grooming ...
F J, White, X T, Hu, R J, Brooderson
openaire   +2 more sources

D1 dopamine receptor activity of anti-Parkinsonian drugs

Life Sciences, 1997
Clinical and preclinical investigations suggest that stimulation of D1 dopamine receptors may be responsible for dyskinesias induced by dopamine agonist treatment of Parkinson's Disease (PD), and that these dyskinesias may be decreased by treatment with a D1 antagonist (clozapine).
G J, Fici, H, Wu, P F, VonVoigtlander, V H, Sethy   +3 more
openaire   +2 more sources